Cousin vs. Sibling Donors in Haplo-HSCT
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation, Donor. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison of Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation From Cousin Donors Versus Sibling Donors in Patients With Hematological Malignancies: A Target Trial Emulation Study
Overview
This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors. The main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT. Study participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.
Primary outcome measures
- Overall survival [Time frame: 2 years after transplantation]
- Graft-versus-host disease-free and relapse-free survival [Time frame: 2 years after transplantation]
- Cumulative incidence of acute graft-versus-host disease [Time frame: 180 days after transplantation]
- Cumulative incidence of chronic graft-versus-host disease [Time frame: 2 years after transplantation]
Secondary outcome measures (4)
- Cumulative incidence of relapse [Time frame: 2 years after transplantation]
- Non-relapse mortality [Time frame: 2 years after transplantation]
- Cumulative incidence of grade III-IV acute graft-versus-host disease [Time frame: 180 days after transplantation]
- Cumulative incidence of extensive chronic graft-versus-host disease [Time frame: 2 years after transplantation]
Eligibility criteria
Inclusion criteria
- Adult patients diagnosed with hematological malignancies, including acute leukemia (AL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and non-Hodgkin lymphoma (NHL)
- Receipt of first haploidentical hematopoietic stem cell transplantation between 2017 and 2024
- Documented exact date of transplantation available in medical charts
- Verifiable donor kinship classified as either cousin or sibiling
- Complete longitudinal follow-up data accessible for outcome assessment
Exclusion criteria
- Prior receipt of any form of hematopoietic stem cell transplantation
- An age difference of more than 18 years between the donor and recipient
- Failure of successful infusion of donor-derived hematopoietic stem cells following conditioning regimen
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The First Affiliated Hospital of Soochow University — Suzhou
Identifiers
NCT: NCT07662382 · TTE2026610